THIS WEBINAR HAS BEEN CANCELED
We apologize for the inconvenience. Stay up to date on upcoming BioPharma Dive webinars and events by subscribing to our newsletter or visiting BioPharmaDive.com

Ninety percent of drug candidates fail to reach the commercial market—and among those failures, 90% are linked to suboptimal target selection. With a product’s odds of success so closely tied to good target characterization, scientists are always looking for the best way to create a supportive foundation for their asset during drug discovery. 

Single-cell RNA sequencing (scRNA-seq) is a proven practice that does exactly that—but its uptake by biopharma organizations has been limited.  A retrospective analysis that examines scRNA-seq data across multiple diseases and tissue types may change this approach. In this webinar, the study’s co-author discusses:

• The current state of scRNA-seq uptake in the pharma industry, including barriers preventing more widespread utilization
• Why this analysis was conducted and what its takeaways may mean for pharma stakeholders
• Methodology, results, limitations, and potential future direction of scRNA-seq

SPEAKER

Virginia Savova, PhD.
Strategic and Scientific Advisor
Scailyte